Clinical trials: Progression Free Survival
Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
The goal of this phase II randomized controlled clinical trial is to evaluate whether adding lubiprostone to standard postoperative maintenance therapy can delay disease progression and recurrence in adult patients with…
- Conditions
- Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer, Peritoneal Metastasis, Colorectal Cancer (CRC)
- Trial name
- NCT07405736
- Testing
- maintenance therapy plus lubiprostone, maintenance therapy
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
Working Out M0 Bipolar Androgen Therapy
The WOMBAT study will test if BAT can prolong the time it takes for nmCRPC prostate cancer to become detectable in other areas of the body (metastatic disease).
- Trial name
- WOMBAT (NCT06594926)
- Testing
- Testosterone Enanthate
- Where
- 12 sites in Australia
- Volunteers
- 69 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Esophageal Squamous Cell Carcinoma
Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma (ESCC) ,20 patients enrolled in Phase Ib PALACE-1(NCT03792347).The results…
- Trial name
- PALACE-2 (NCT04435197)
- Testing
- Pembrolizumab Injection
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- Ruijin Hospital
Solid Neoplasms, Non-Small Cell Lung Cancer
PET/CT-Based Intratumoral Heterogeneity and Multimodal Imaging for Tumor Diagnosis and Prognosis
Background \& Rationale: Intratumoral heterogeneity (ITH) is a recognized hallmark and critical driver of therapeutic resistance, rapid disease progression, and poor survival across solid malignancies, notably advanced…
- Trial name
- NCT07906158
- Testing
- This is an observational study with no intervention.
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Shengjing Hospital
Non-small Cell Lung Cancer
IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents.
- Trial name
- IMMUNOLUNG (NCT07608835)
- Testing
- prospective collection of blood and tumor samples
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Paoli-Calmettes
Non-small Cell Lung Cancer, Progression, Disease
Energy for Lymphocytes
CERTIM is a cohort created in July 2015 to set up a multidisciplinary follow-up of cancer patients treated with immune checkpoint inhibitors.
- Trial name
- ELY (NCT04879316)
- Testing
- Resting Energy Expenditure measurement
- Where
- France
- Volunteers
- 144 people
- Sponsor
- Hôpital Cochin
Cutaneous Adverse
Association Between Drug-related Cutaneous Adverse Events and Progression Free Survival in Patients Treated with Enfortumab Vedotin
Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) targeting nectin-4. In patients with metastatic urothelial carcinoma, EV in combination with pembrolizumab (anti-PD1) provides significantly better progression-free and…
- Trial name
- SURVSKINTOX-EV (NCT06682845)
- Testing
- Collection of data in patients' medical files
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Hospices Civils de Lyon